Impact of iron overload in myelodysplastic syndromes

Blood Reviews

Volumn 23, Issue SUPPL. 1, 2009, Pages

  Fenaux, Pierre ^a,b   Rose, Christian ^a,c  

^a Groupe Francophone des Myélodysplasies GFM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

Author keywords

Iron chelation therapy; Iron overload; Myelodysplastic syndromes

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FREE RADICAL; HEPCIDIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CREATININE BLOOD LEVEL; DISEASE COURSE; ENDOCRINE DISEASE; ERYTHROPOIESIS; FUNGUS GROWTH; HEART DISEASE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIVER DYSFUNCTION; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME;

HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES;

EID: 73149112391     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(09)70005-0     Document Type: Review

References (54)

1. Aul C., Giagounidis A., and Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 73 (2001) 405-410
2. Ma X., Does M., Raza A., and Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109 (2007) 1536-1542
3. Malcovati L., Della Porta M.G., Laarakkers C.M., et al. Erythroid activity, transfusion iron overload, and hepcidin levels in patient with myelodysplastic syndrome. Blood 112 (2008) abstract 2676.
4. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111 (2008) 574-582
5. Porter J.B. Practical management of iron overload. Br J Haematol 115 (2001) 239-252
6. Sanz G.F., Sanz M.A., Vellespí T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74 (1989) 395-408
7. Kelaidi C, Stamatoullas A, Beyne-Rauzy O, et al. Myelodysplastic syndrome (MDS) in France: results of a one-week cross-sectional survey on daily practice management in 919 patients by the GFM. Haematologica 2009; in press.
8. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
9. Grootveld M., Bell J.D., Halliwell B., et al. Non-transferrin-bound iron in plasma or serum from patients with idiopathic haemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 264 (1989) 4417-4422
10. Breuer W., Greenberg E., and Cabantchik Z.I. Newly delivered transferrin iron and oxidative cell injury. FEBS Lett 403 (1997) 213-219
11. Au W.Y., Lam W.W.M., Chu W.W.C., et al. A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodyplasia and aplastic anemia with raised ferritin levels. Hematol Oncol 26 (2008) 225-228
12. Chacko J., Pennell D.J., Tanner M.A., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138 (2007) 587-593
13. Lu J.P., and Havashi K. Selective iron deposition in pancreatic islet B cells of transfusional iron-overloaded autopsy cases. Pathol Int 44 (1994) 194-199
14. Konen E., Ghoti H., Goitein O., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol 82 (2007) 1013-1016
15. Di Tucci A.A., Matta G., Deplano S., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 93 (2008) 1385-1388
16. Buja L.M., and Roberts W.C. Iron in the heart. Etiology and clinical significance. Am J Med 51 (1971) 209-221
17. Jensen P.D., Jensen F.T., Christensen T., et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 101 (2003) 4632-4639
18. Cortelezzi A., Cattaneo C., Cristiani S., et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. Hematol J 1 (2000) 153-158
19. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 15 (2008) 169-175
20. Huang H., Constante M., Layoun A., and Santos M.M. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood 113 (2009) 3593-3599
21. Tamary H., Shalev H., Perez-Avraham G., et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 112 (2008) 5241-5244
22. Tanno T., Porayette P., Sripichai O., et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114 (2009) 181-186
23. Truksa J., Lee P., and Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 113 (2009) 688-695
24. Nearman Z.P., Szpurka H., Serio B., et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 82 (2007) 1076-1079
25. Cazzola M., Barosi G., Gobbi P.G., et al. Natural history of idiopathic refractory sideroblastic anemia. Blood 71 (1988) 305-312
26. Schafer A.I., Cheron R.G., Dluhy R., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304 (1981) 319-324
27. Schafer A.I., Cheron R.G., Dluhy R., et al. Clinical consequences of acquired sideroblastic anemia. Blood 71 (1988) 305-312
28. Malcovati L., Della Porta M.G., and Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91 (2006) 1588-1590
29. Sanz G., Nomdedeu B., Such E., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112 (2008) abstract 640.
30. Chee C.E., Steensma D.P., Wu W., et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 83 (2008) 611-613
31. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83 (2008) 858-861
32. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meet the eye?. Blood (2009) [Epub ahead of print].
33. Takatoku M., Uchiyama T., Okamoto S., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Hematol 78 (2007) 487-494
34. Goldberg S.L., Mody-Patel N., and Chen E.R. Clinical and economic consequences of myelodysplastic syndromes in the United States: an analysis of the Medicare database. Blood 112 (2008) abstract 636.
35. Asmis T.R., Ding K., Seymour L., et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26 (2008) 54-59
36. Della Porta M.G., Kuendgen A., Malcovati L., et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra- hematological comorbidities on survival of patients with MDS. Blood 112 (2008) abstract 2677.
37. Sorror M., Storer B., Sandmaier B.M., et al. Hematopoietic cell transplantationcomorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112 (2008) 1992-2001
38. Wood J.C., Otto-Duessel M., Aguilar M., et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 112 (2005) 535-543
39. Ferte C., Ernst O., Beyne-Rauzy O., et al. Clinical relevance of cardiac iron overload estimated by MRI T2* in regularly transfused low risk MDS. Blood 108 (2006) abstract 2666.
40. Ghoti H., Amer J., Winder A., et al. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 79 (2007) 463-467
41. Leitch H.A., Wong D.H.C., Leger C.S., et al. Improved leukemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. Blood 110 (2007) abstract 1469.
42. Rose C., Brechignac S., Vassilief D., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 110 (2007) abstract 249.
43. Rose C, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res; in press.
44. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109 (2007) 4586-4588
45. Platzbecker U., Bornhäuser M., Germing U., et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 14 (2008) 1217-1225
46. Pullarkat V., Blanchard S., Tegtmeier B., et al. Iron overload adversely affect outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 42 (2008) 799-805
47. Rose C., Ernst O., Hecquet B., et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica 92 (2007) 850-853
48. Sahlstedt L., Ebeling F., von Bonsdorff L., et al. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 113 (2001) 836-838
49. Dürken M., Nielsena P., Knobel S., et al. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic Biol Med 22 (1997) 1159-1163
50. Caroline L., Rosner F., and Kozinn P.J. Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood 34 (1969) 441-451
51. Karp J.E., and Merz W.G. Association of reduced total iron binding capacity and fungal infections in leukemic granulocytic patients. J Clin Oncol 4 (1986) 216-220
52. von Bonsdorff L., Sahlstedt L., Ebeling F., et al. Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. FEMS Immunol Med Microbiol 37 (2003) 45-51
53. Boelaert J.R., de Locht M., van Cutsem J., et al. Mucormycosis during deferoxamine therapy is a siderophore mediated infection: in vitro and in vivo animal studies. J Clin Invest 91 (1993) 1979-1986
54. Ibrahim A.S., Spellberg B., and Edwards Jr. J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 21 (2008) 620-625